Where Biotech CEOs Come From
Executive SummaryMany of the CEOs that took biotech firms public from 1995-96 have deep roots in the biotech industry. Unlike previous waves of CEOs, these execs are prized more for marketing shares than drugs.
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.